One of the reasons for Illumina Inc.’s attraction to the noninvasive prenatal testing space is that it’s a large but relatively bounded market with only a handful of players, says president & CEO Jay Flatley. It’s different than the cancer market, for example, which may have hundreds of subsegments, lots of players, and very little in the way of intellectual property, he says.
As a result, Illumina changed its molecular diagnostics strategy when it bought Verinata Health Inc., opting to become involved...
